Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT05157763

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Led by MediWound Ltd · Updated on 2021-12-15

32

Participants Needed

3

Research Sites

48 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma. In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.

CONDITIONS

Official Title

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female greater than age 18
  • One primary superficial or nodular basal cell carcinoma lesion confirmed by biopsy
  • Lesion located on the trunk or upper extremities, excluding hands
  • Lesion present for no longer than 4 years
  • Lesion diameter between 5 and 10 mm
  • Ability to understand the study, follow the protocol, and provide written informed consent
Not Eligible

You will not qualify if you...

  • Evidence of Gorlin syndrome, neoplastic diseases (excluding actinic lesions), metastatic tumors, or tumors with high metastatic risk
  • Other malignant skin cancers at the lesion site
  • Morphea-type basal cell carcinoma at the lesion site
  • Signs of infection at the lesion site, such as discharge or abscess
  • Any dermatological disease in or around the lesion area except chronic actinic damage
  • History of allergy or sensitivity to pineapples, papaya, bromelain, papain, latex proteins, bee venom, or olive tree pollen
  • Undergoing renal or peritoneal dialysis
  • Significant or unstable heart, lung, liver, blood, immune, or life-threatening conditions
  • Current acute injury or disease affecting welfare or study participation
  • Severe alcohol or drug use disorder within the last 12 months
  • Pregnant or nursing women
  • Participation in another investigational drug or intervention trial within 4 weeks prior or during this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Center for Clinical and Cosmetic Research

Aventura, Florida, United States, 33180

Actively Recruiting

2

Moore Clinical Research, Inc.

Brandon, Florida, United States, 33511

Not Yet Recruiting

3

Center for Clinical Studies, LTD. LLP

Webster, Texas, United States, 77598

Actively Recruiting

Loading map...

Research Team

L

Limor Dinur Klein, PhD

CONTACT

K

Keren David, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here